Loading live market data…

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

$21.43 USD

$0.41 (1.95%)

Volume
1.89M
Average Volume
2.52M
Market Capitalization
$3.43B
P/E Ratio
-65.46
Dividend Yield
0.00%
Price Target
$21.50
Year High
$22.80
Year Low
$9.96
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.35

Industry, Sector & symbol

Stock Exchange NASDAQ
CEO Chad Robins
Industry Biotechnology
Sector Healthcare
Current Symbol ADPT
CUSIP 00650F109
CIK 0001478320
Web https://www.adaptivebiotech.com
Phone 206 659 0067
Currency USD
Employees 624
Country US

Liquidity

Debt-to-Equity Ratio 0.96
Payout Ratio 0.00
Current Ratio 3.35
Quick Ratio 3.22
Cash Ratio 0.89

Sales & Book Value

Annual Sales $276.98M
Price / Sales 11.61
Cash Flow -0.19
Price / Cash Flow -116.12
Price / Book 15.41

Price Target and Rating

Average Stock Price Forecast $21.50
High Stock Price Forecast $22.00
Low Stock Price Forecast $20.00
Forecast Upside/Downside -0.33%
Consensus Rating Strong Sell
Rating Score(0-5) 1
Research Coverage 17 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.39
Trailing P/E Ratio -65.46
PEG Ratio -0.51
P/E Growth -0.51
Net Income $-59.5M
Net Margin -16.82%
Pretax Margin -16.81%
Return on Equity -24.26%
Return on Assets -9.82%

Financials Score

AltmanZ Score 4.15
Piotroski Score 4.00
Working Capital 204.8M
Total Assets 505.94M
Ebit -38.97M
Market Cap 3.36B
Total Liabilities 281.7M

Poll Results

About Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal r ... esidual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run

2026-07-12 17:38:38

Approximately 386,000 shares were liquidated for a total transaction value of $8.5 million on July 2, 2026. This transaction consisted entirely of directly held shares.

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

2026-07-09 16:05:00

SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2026 after market close on Wednesday, July 29, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Adaptive Biotechnologies Business Separation May Unlock Greater Value

2026-06-17 13:21:47

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) on Monday announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

2026-06-17 06:00:00

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of 100% and to repurchase $25 million of common stock to reduce potential dilution Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business SEATTLE, June 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $250 million aggregate principal amount of notes.

Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses

2026-06-16 10:42:45

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares are trading higher during Tuesday's session as the company has announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.

Adaptive Biotechnologies plans separation of immune medicine platform

2026-06-15 16:47:03

Adaptive Biotechnologies said on Monday it planned to separate its immune medicine ​business from its residual cancer-testing unit, ‌as it reviews options for the drug-discovery business and focuses on testing.

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

2026-06-15 16:10:00

MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

2026-06-15 16:05:00

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to $25 million of common stock to reduce potential dilution Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Adaptive Biotechnologies also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of notes.

Frequently Asked Questions

What is the current Adaptive Biotechnologies Corporation (ADPT) stock price?

Adaptive Biotechnologies Corporation(NASDAQ:ADPT) stock price is $21.43 in the last trading session. During the trading session, ADPT stock reached the peak price of $22.8 while $9.9551 was the lowest point it dropped to. The percentage change in ADPT stock occurred in the recent session was 1.95% while the dollar amount for the price change in ADPT stock was $0.41.

ADPT's industry and sector of operation?

The NASDAQ listed ADPT is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of ADPT?

Susan Bobulsky | Chief Commercial Officer of MRD
Clarice McCauley | Head of Legal, Corporate Secretary, VP & Chief Compliance Officer
Julie Rubinstein | President & Chief Operating Officer
Karina Calzadilla | Vice President of Investor Relations
Harlan S. Robins | Co-Founder & Chief Scientific Officer

How many employees does ADPT have?

Number of ADPT employees currently stands at 624. ADPT operates from 1165 Eastlake Avenue East, Seattle, WA 98109, US.

Link for ADPT official website?

Official Website of ADPT is: https://www.adaptivebiotech.com

How do I contact ADPT?

ADPT could be contacted at phone #206 659 0067 and can also be accessed through its website. ADPT operates from 1165 Eastlake Avenue East, Seattle, WA 98109, US.

How many shares of ADPT are traded daily?

The average number of ADPT shares traded daily for last 3 months was 2.52M.

What is the market cap of ADPT currently?

The market value of ADPT currently stands at $3.43B with its latest stock price at $21.43